Breaking New Ground in ALS Research

Background

Amyotrophic Lateral Sclerosis (ALS) remains one of the most complex neurological diseases to understand and treat. That’s why we’re working with forward-thinking partners to move promising research forward as rapidly as possible.

Watch the webinar to hear about Neurizon’s NUZ-001, a potential game-changer in ALS therapy, and learn how Ncardia’s cutting-edge iPSC-based platforms are redefining preclinical research. 

This is a unique opportunity to hear directly from leaders at Ncardia and Neurizon as they share exclusive insights into the latest scientific progress shaping the future of ALS therapies.